ID   Raji-APC-Null
AC   CVCL_E3JB
WW   https://www.invivogen.com/raji-apc-null
CC   Population: African; Nigerian.
CC   Biotechnology: Activating control antigen presenting cell (APC) for anti-immune checkpoint cell-based assay (InvivoGen).
CC   Characteristics: Transfected with a specific antigenic peptide complexed with HLA molecules ([HLA::peptide]) (InvivoGen).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P33967; B.cereus Bsr.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0511 ! Raji
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//